At the end of the latest market close, CASI Pharmaceuticals Inc. (CASI) was valued at $3.00. In that particular session, Stock kicked-off at the price of $2.98 while reaching the peak value of $3.30 and lowest value recorded on the day was $2.93. The stock current value is $3.26.
Recently in News on January 8, 2021, CASI Pharmaceuticals, Inc. To Present At H.C. Wainwright Bioconnect Conference. CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that Dr. Wei-Wu He, Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the H.C.Wainwright Bioconnect Conference. Details for the virtual conferences are as follows. You can read further details here
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
CASI Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.30 on 01/13/21, with the lowest value was $2.76 for the same time period, recorded on 01/05/21.
CASI Pharmaceuticals Inc. (CASI) full year performance was -1.21%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, CASI Pharmaceuticals Inc. shares are logging -1.81% during the 52-week period from high price, and 183.48% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.15 and $3.32.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1150580 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the CASI Pharmaceuticals Inc. (CASI) recorded performance in the market was 10.51%, having the revenues showcasing 85.23% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 392.90M, as it employees total of 125 workers.
The Analysts eye on CASI Pharmaceuticals Inc. (CASI)
During the last month, 0 analysts gave the CASI Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.09, with a change in the price was noted +1.42. In a similar fashion, CASI Pharmaceuticals Inc. posted a movement of +77.17% for the period of last 100 days, recording 421,373 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CASI is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of CASI Pharmaceuticals Inc. (CASI)
Raw Stochastic average of CASI Pharmaceuticals Inc. in the period of last 50 days is set at 97.17%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 95.70%. In the last 20 days, the company’s Stochastic %K was 81.81% and its Stochastic %D was recorded 73.82%.
Considering, the past performance of CASI Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 10.51%. Additionally, trading for the stock in the period of the last six months notably improved by 55.24%, alongside a downfall of -1.21% for the period of the last 12 months. The shares increased approximately by 16.01% in the 7-day charts and went down by 21.19% in the period of the last 30 days. Common stock shares were driven by 85.23% during last recorded quarter.